How to Get Rezdiffra (Resmetirom) in Wisconsin

What resmetirom actually is, and why "getting it" is more than a legal question

Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist taken as a once-daily tablet. It is not a compounded peptide, a supplement, or a generic; it is a single branded, patented small-molecule drug approved under the name Rezdiffra. It should not be confused with other MASH-pipeline drugs or with thyroid replacement hormones, which act on different receptor subtypes and are not interchangeable with resmetirom.

The FDA approved resmetirom in March 2024 for adults with MASH and moderate-to-advanced liver fibrosis (F2-F3), to be used with diet and exercise. This was an accelerated approval based on liver biopsy improvements observed in a randomized trial, not yet on confirmed long-term clinical outcomes such as reduced cirrhosis or liver-related mortality; that confirmatory evidence is still being generated. Wisconsin does not have any state-specific legal barrier to prescribing resmetirom: it is not a controlled substance, telehealth prescribing of non-controlled drugs is broadly permitted in the state, and the drug can be dispensed by any pharmacy licensed to operate there. The genuine bottleneck for most Wisconsin patients is not legality; it is documenting F2-F3 fibrosis with an accepted test and then clearing an insurer's prior-authorization process, since resmetirom is expensive and payers require objective evidence before covering it.

Is it legal to get a Rezdiffra prescription by telehealth in Wisconsin?

Yes, in general. Wisconsin permits synchronous audio-video telehealth prescribing of non-controlled medications, and resmetirom carries no DEA schedule, so no in-person visit is legally mandated before a prescription can be written. A licensed Wisconsin-based physician, nurse practitioner, or physician assistant (or an out-of-state provider licensed in Wisconsin or covered under a recognized interstate compact) can evaluate labs and imaging over telehealth and issue the prescription in that visit if the diagnostic documentation supports it. The exact statutory citations and any recent updates to Wisconsin's telehealth rules should be verified against the Wisconsin Department of Safety and Professional Services or the Medical Examining Board directly, since administrative rules are revised periodically and a specific section number from an older document may no longer be current.

What has to be documented before a prescription makes clinical sense

Regardless of whether the visit is in person or by telehealth, prescribers generally need baseline data before starting resmetirom, both to follow FDA labeling and to satisfy insurer requirements:

• Liver enzymes and hepatic function (AST, ALT, bilirubin, albumin, platelets)
• A fibrosis-stage assessment: either a validated non-invasive test such as transient elastography (FibroScan) showing stiffness consistent with F2-F3 fibrosis, or a liver biopsy
• A lipid panel, because resmetirom is associated with a transient rise in LDL cholesterol during the first weeks of treatment
• Thyroid function testing, since uncontrolled thyroid disease is a relevant confounder for a thyroid receptor agonist
• Pregnancy testing where applicable

The American Association for the Study of Liver Diseases has published practice guidance favoring non-invasive fibrosis testing as a first-line approach, reserving biopsy for indeterminate cases. Readers should confirm the current version of that guidance and any Wisconsin-specific insurer preference (some plans still request a FIB-4 score or a specific FibroScan cutoff) rather than assume any single number is a universal requirement, since payer criteria vary and change.

Will Wisconsin Medicaid or commercial insurance actually cover it?

Wisconsin Medicaid (BadgerCare Plus and fee-for-service) has covered resmetirom with prior authorization since shortly after FDA approval, and PA generally requires a documented MASH diagnosis, objective fibrosis staging, and evidence of relevant metabolic comorbidities. Commercial insurers operating in Wisconsin (for example Anthem BCBS of Wisconsin, Quartz, Security Health Plan, and Group Health Cooperative) each run their own PA process with their own criteria and turnaround expectations.

This is exactly the kind of fact that goes stale quickly. Specific PA turnaround windows, required ICD-10 codes, whether a specialist co-signature is required, and denial or appeal patterns are plan-specific and change over time; a number that was accurate in one calendar year can be wrong the next. Anyone relying on a specific number for their own coverage decision should call their plan or Wisconsin Medicaid directly rather than treat any published estimate as current. The same caution applies to cash price and manufacturer copay assistance: list price and program terms are set by the manufacturer and change without notice, so a specific dollar figure printed on any article, including this one, needs a same-day check against the manufacturer's current program page before a patient plans around it.

Compounded resmetirom: a point that needs care, not convenience

Some articles about Rezdiffra access mention 503A compounding pharmacies as an alternative dispensing channel, implying a cost-saving workaround. This deserves caution rather than a simple yes. Under federal law, compounding pharmacies are generally restricted from compounding a copy of a commercially available, FDA-approved drug unless there is a documented clinical reason a patient cannot use the manufactured product (for example, an allergy to an excipient) or the drug is in a documented shortage. Resmetirom is a small molecule sold as branded tablets by a single manufacturer, and nothing in the public record indicates it is in shortage. Whether, and under what narrow circumstances, a Wisconsin-licensed 503A pharmacy could lawfully compound a resmetirom formulation is a pharmacy-law and prescriber-judgment question that should be verified with the Wisconsin Pharmacy Examining Board and a pharmacist, not assumed as a routine, cost-saving option. Readers should not treat compounded resmetirom as an established, standard access pathway based on this page.

Who can write the prescription

Physicians (MD/DO) have full prescriptive authority in Wisconsin. Advanced practice nurse prescribers have held independent prescriptive authority in the state since 2018 and can prescribe resmetirom without physician oversight, subject to their own scope-of-practice rules. Physician assistants prescribe under a collaborative agreement with a supervising physician. No Wisconsin regulation limits resmetirom prescribing to hepatologists specifically, but insurers commonly expect the prescriber to have documented experience managing liver or metabolic disease as part of prior authorization; a gastroenterologist, endocrinologist, or internist with MASH experience typically satisfies this in practice. Readers in rural counties without nearby hepatology access may find telehealth the more practical route, but should confirm that a chosen platform actually has clinicians licensed in Wisconsin and willing to manage the required lab monitoring.

Moving an existing prescription to Wisconsin

Standard interstate pharmacy transfer rules apply: a Wisconsin-licensed pharmacy can request the prescription, refill count, and prescriber details from the originating pharmacy. If the prior authorization was tied to another state's Medicaid program, a new PA will generally be required in Wisconsin; commercial PAs held through a national pharmacy benefit manager sometimes carry over without resubmission, but this depends on the specific plan and should be confirmed rather than assumed. Patients switching pharmacies should ask their current pharmacy about a short bridge supply to avoid a treatment gap while the transfer and any new PA are processed.

Side effects and what monitoring should look like

In the pivotal randomized trial supporting FDA approval, the most common adverse effects reported with resmetirom were diarrhea and nausea, generally mild and occurring early in treatment, along with a transient rise in LDL cholesterol in the first weeks that tended to resolve with continued treatment in most participants. Selectivity for the liver-predominant THR-beta receptor over the cardiac THR-alpha receptor is the proposed mechanism for why clinically significant thyrotoxicosis was not seen in that trial population; this is a mechanistic explanation, not a guarantee for every individual patient. Typical monitoring includes repeat liver enzymes and a lipid panel around four weeks after starting, again around twelve weeks, and periodic reassessment of fibrosis status thereafter. Anyone who develops signs of liver injury (jaundice, severe abdominal pain, dark urine) or a severe allergic reaction should seek urgent medical evaluation rather than wait for a scheduled follow-up.

A national survey of hepatology and gastroenterology providers conducted around the time of resmetirom's approval found meaningful variability in provider familiarity with MASLD/MASH pharmacotherapy, including newer weight-management-adjacent treatments, which may partly explain uneven prescribing patterns and why some patients encounter providers less comfortable initiating resmetirom than others (Sheka et al., 2026). This is a plausible contributor to access variability, not a Wisconsin-specific finding, and should be read as background rather than a state-level statistic.

What is established, what is plausible, and what is not established

Established: Resmetirom is FDA-approved for MASH with F2-F3 fibrosis; it is not a controlled substance; Wisconsin permits telehealth prescribing of non-controlled drugs; and the drug requires baseline liver, lipid, and thyroid testing plus objective fibrosis staging before and during treatment.

Plausible but requiring current verification: Specific prior-authorization turnaround times, exact FIB-4 or FibroScan cutoffs used by a given Wisconsin payer, manufacturer copay program terms, and cash price. These change and were not independently confirmed against a live Wisconsin-specific source for this draft.

Not established on the evidence available here: That 503A compounding of resmetirom is a routine, lawful, cost-saving option for Wisconsin patients; that any specific Wisconsin statute section governs telehealth prescribing without independent confirmation of its current text; and any precise Wisconsin-specific MASH prevalence figure, since no Wisconsin-specific epidemiological source was available to support one.

Verification checklist: stable facts versus facts that expire

Use this before acting on anything above. Items in the first column are unlikely to change quickly; items in the second column need a same-day check against a primary or payer source before you rely on them.